<DOC>
	<DOCNO>NCT00703300</DOCNO>
	<brief_summary>This phase I trial study side effect best dose bortezomib give together decitabine treat patient acute myeloid leukemia . Bortezomib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , decitabine , work different way stop growth cancer cell , either kill cell stop divide . Giving bortezomib together decitabine may kill cancer cell .</brief_summary>
	<brief_title>Decitabine Bortezomib Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) bortezomib ( Velcade , PS-341 ) combination decitabine patient acute myeloid leukemia ( AML ) II . To define specific toxicity dose limit toxicity ( DLT ) decitabine plus bortezomib combination SECONDARY OBJECTIVES : I . To determine overall response rate ( ORR ) . II . To determine rate complete remission ( CR ) decitabine plus bortezomib AML III . To correlate biological activity decitabine demethylating agent ( change target gene methylation gene expression , DNMT1 protein expression , global methylation ) clinical endpoint plasma pharmacokinetics decitabine . IV . To characterize biological activity bortezomib potential demethylating agent V. To correlate intracellular concentration decitabine-triphosphate global DNA methylation biological endpoint well clinical response . VI . To explore biologic role microRNAs determine clinical response decitabine plus bortezomib combination achievement pharmacodynamic endpoint . OUTLINE : This dose-escalation study bortezomib . Patients receive decitabine intravenously ( IV ) 1 hour day 1-5 1-10 bortezomib IV day 5 8 day 5 , 8 , 12 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Once maximum tolerate dose determine , additional 6 patient treat recommended phase II dose . After completion study treatment , patient follow least 30 day .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Diagnosis acute myeloid leukemia ( AML ) , meet one follow criterion : Relapsed refractory disease ( ≥ 18 year age ) Previously untreated disease ( ≥ 60 year age ) Secondary AML therapyrelated AML allow No granulocytic sarcoma sole site disease No active relapse CNS disease No advance malignant solid tumor ECOG performance status 02 Life expectancy &gt; 6 month ( patient comorbid illness ) Total bilirubin &lt; 2.0 mg/dL AST ALT &lt; 2.5 time upper limit normal Creatinine &lt; 2.0 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Patients HIV infection eligible provide follow criterion meet : No history AIDS Has sufficiently high CD4 count ( &gt; 400/mm³ ) Has low HIV viral load ( &lt; 30,000 copies/mL plasma ) Does require antiHIV therapy No uncontrolled active infection No history allergic reaction attribute compound similar chemical biological composition decitabine bortezomib easily manage No hypersensitivity boron mannitol No concurrent uncontrolled illness include , limited , follow : Symptomatic congestive heart failure Unstable uncontrolled angina pectoris Serious cardiac arrhythmia Myocardial infarction within past 6 month New York Heart Association class IIIIV heart failure Severe uncontrolled ventricular arrhythmia Acute ischemia active conduction system abnormality ECG No serious medical psychiatric illness social situation would preclude participation study No preexist neuropathy ≥ grade 2 No serious neurologic toxicity would significantly increase risk complication bortezomib therapy Recovered prior therapy ( toxicity &lt; grade 2 ) More 14 day since prior investigational agent More 2 week since prior chemotherapy ( 6 week nitrosoureas mitomycin C ) radiotherapy Prior decitabine azacitidine myelodysplastic syndrome ( MDS ) AML allow More 6 month since prior decitabine , azacitidine , bortezomib No concurrent palliative radiotherapy No concurrent investigational agent No concurrent direct antileukemia therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>